8. Vincent Forlenza - Becton Dickinson

2014 pay: $10.9 million
2015 pay: $11.7 million

Becton Dickinson ($BD) CEO Vincent Forlenza had a lot on his plate last year after the company announced in 2014 that it would snatch up CareFusion in a $12.2 billion deal. But Forlenza helped chart progress during the company’s first combined year, including revenue growth of 5.3% and double-digit earnings growth.

Under Forlenza’s direction, Becton Dickinson also expanded in Medication Management and Genomics. The company’s recent progress is “a testament to all the hard work from Becton Dickinson and CareFusion associates around the world,” Forlenza said on the company’s Q4 2015 earnings call. Becton Dickinson is “looking to the future with confidence,” he added.

The progress reflects Forlenza’s confidence in the deal, which was meant to give Becton Dickinson more hospital offerings. In particular, the company is looking to provide “end-to-end solutions that increase efficiencies, reduce medication errors and improve patient safety in both hospitals and pharmacies,” Forlenza said at the time of the deal.

Forlenza took home a pretty penny for his work in 2015. The CEO’s 2015 pay included a $1 million base salary, $5.3 million in stock awards, $3.5 million in options and $1.6 million in non-equity incentives.

- here’s Becton Dickinson’s proxy statement

For more:
Becton Dickinson plans respiratory asset sale in wake of CareFusion merger
BD to buy CareFusion for $12.2B to become more hospital-focused
Becton Dickinson ordered to notify customers about false-advertising claims for safety syringes

8. Vincent Forlenza - Becton Dickinson

Suggested Articles

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.